Clinical Trial Detail

NCT ID NCT02707666
Title A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Cisplatin + Pemetrexed Disodium

Age Groups: adult

No variant requirements are available.